How many more innocent lives must be lost?

🎬 Registration Open for Our Next Live Webinar: Innovations and Future Outlook in Radiotheranostics 🧑‍⚕️Prof Munir Ghesani & Prof Christophe Deroose 📅17.04 👉 zoom.us/webinar/regist… 𝗥𝗮𝗱𝗶𝗼𝘁𝗵𝗲𝗿𝗮𝗻𝗼𝘀𝘁𝗶𝗰𝘀, 𝗮𝗻 𝗮𝗱𝘃𝗮𝗻𝗰𝗲𝗱 𝗮𝗽𝗽𝗿𝗼𝗮𝗰𝗵 𝘁𝗼 𝗳𝗶𝗴𝗵𝘁 𝗰𝗮𝗻𝗰𝗲𝗿

🔔 Abstract Submission Deadline is Almost Here! 🔔 Time is running out—just a few days left to submit your abstract for #EANM25! Here’s your checklist: ✅ Finalise your work ✅ Give it a final polish ✅ Submit it here 👉 bit.ly/3Xsd9W4

It is not all about tumor shrinkage after PRRT. In this NETTER-1 analysis, PFS and OS were not different in patients where tumor shrinkage was seen. Not a new observation but a topic I discuss every week with patients. Benefits can be seen w/o high ORR... onlinelibrary.wiley.com/doi/10.1002/ca…

Incredible prognostic power of PSMA PET from the updated PROMISE large international registry (PPP2): 3 and 5-yr survival data. Superior to NCCN risk score. Data across initial stage, biochemical recurrence, "non-metastatic" castration-resistant, mSPC, MCRPC !! Just out in

Nuevos tratamientos en desarrollo en neoplasias neuroendocrinas #ASCO25 👩🏼‍🔬ABBV-706 (SEZ6 ADC) ✅️Expresión de SEZ6 en NET y NEC ✅️ORR 36%, PFS 7m ✅️Actividad en carcinoma medular de tiroides. ✅️Continua desarrollo en monoterapia +/- budigalimab +/- quimio.

Nuclear is the best source of energy across nearly all the factors that matter. It's the safest, cleanest, densest, most sustainable, geopolitically stable, predictable, dispatchable, and can be cheap. 1. SAFEST It kills 1000x less than coal

🔊🔊 Ipsen receives positive CHMP opinion for Cabometyx® in previously treated advanced neuroendocrine tumors 🙌🏼 A new treatment option for ALL NET patients!! 👏🏼 ⁦Grupo GETNE⁩ ⁦NET- ESPAÑA⁩ ⁦NET Research Foundation⁩ ipsen.com/press-releases…

Extravasation Frequency of [177Lu]Lu-DOTATATE: Insights and Implications Derived from 1,314 Cycles of Treated Patients—A Single-Site Analysis | Journal of Nuclear Medicine jnm.snmjournals.org/content/early/…

#VIOLET Study of Terbium-161 (161Tb) - first trial of Beta/Auger therapy. Recently presented #ASCO25. Now out in The Lancet Oncology : thelancet.com/journals/lanon… 🟣 30 patient trial in prostate cancer. No dose limiting toxicities at highest level of radioactivity (7.4 GBq) 🟣Very few

Standardization of PET/CT Performance Requirements for Whole-Body Quantitative Imaging: An International Proposal | Journal of Nuclear Medicine jnm.snmjournals.org/content/early/…

🌏 We are pleased to announce that the RLT Academy platform now provides subtitles in Korean, Japanese, and Chinese (simplified) across the available educational content. Take a look today and spread the word 👉 rltacademy.eu rltacademy.eu

Just in time for #ESMOGI25 ESMO - Eur. Oncology, our paper on the Dutch-Belgian DBNETS SAUNA trial on continuation of somatostatin analogues in #NET after progression on first-line treatment is out! NETwerk Thanks to funders ZonMw & #KCE BMJ_Open bmjopen.bmj.com/content/15/7/e…

¹⁷⁷Lu-DOTATATE is cost-effective as a first-line treatment for patients with grade 2 or 3, well-differentiated, advanced gastroenteropancreatic #NeuroendocrineTumors. ow.ly/Zzw150W9YMP #NuclearMedicine Wolfgang Kunz Marcus Unterrainer MatthiasBrendel LenaUnterrainer

Exciting news on the #EANMJournals! 🆕 #EANM now has 2 dedicated open-access journals published by Elsevier: 🔹 The EANM Journal 🔹 EANM Innovation 🔗 Find out more: eanm.org/news/eanm-jour… We look forward to the next steps. Stay tuned! #NuclearMedicine

Foregoing Nonclinical Dosimetry Studies to Support First-in-Human Studies of Certain PET Radiopharmaceuticals | Journal of Nuclear Medicine jnm.snmjournals.org/content/early/…

🚨Online today: Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant #prostatecancer in #ENZAp (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial thelancet.com/journals/lanon…